Core Viewpoint - The company has received approval from the China Securities Regulatory Commission for the conversion of approximately 182.6 million unlisted shares into H-shares for full circulation, which is a significant step towards enhancing its market presence and liquidity [1] Group 1: Regulatory Approval - The company has completed the filing for the conversion of about 182.6 million unlisted shares into H-shares for full circulation [1] - If the conversion and listing are not completed within 12 months from the issuance date, the company will need to update its filing materials with the China Securities Regulatory Commission to continue the process [1] Group 2: Strategic Development - The company showcased its "Globalization 2.0" strategy at the JPM 2026 conference, outlining its future innovation pipeline and development plans [1] - Over the next five years, the company anticipates more than 40 new clinical research applications to be approved [1] - By 2030, the company expects to have over 20 products launched globally, with 15 of them likely to enter the European and American markets [1] Group 3: Product Pipeline and Market Focus - The company plans to commercialize more Antibody-Drug Conjugates (ADCs), bispecific antibodies, and T-cell engagers (TCEs) across four major therapeutic areas: oncology, autoimmune diseases, metabolism, and central nervous system disorders [1] - With the enhancement of its global commercialization capabilities, the company is poised for further growth in overseas revenue, solidifying its foundation as an international biopharmaceutical company [1] Group 4: Market Performance - As of January 16, the company's stock has increased by 19.63% since the beginning of the year and has seen a 194.18% increase over the past 250 days [1] - The total market capitalization of the company stands at 37.1 billion Hong Kong dollars [1]
复宏汉霖 (02696.HK) 全流通备案落地，全球化 2.0 战略加速起航